PDCD1 and colorectal carcinoma: Analysis of clinical data from The Cancer Genome Atlas (TCGA) corroborated these findings, showing that CRC patients treated with anti-PD-1 had improved overall survival compared to those treated with anti-PD-L1 (Figure 1E).